Klaria Pharma (KLAR) Q4 2024 earnings summary

Executive summary

• Achieved key milestones: EU market approval for Sumatriptan Alginatfilm and a major licensing deal with CNX Therapeutics for Europe and the UK, with initial launches planned for H2 2025.

• Transitioning from a development-focused to a commercial-stage pharma company, aiming for further licensing outside Europe in the next 12 months.

Financial highlights

• Net sales for 2024 were 2.2 MSEK, down from 8.5 MSEK year-over-year; Q4 net sales were 1.1 MSEK, down from 1.3 MSEK.

• R&D expenses for 2024 totaled 22.1 MSEK (24.9 MSEK prior year); Q4 R&D was 9.3 MSEK (1.9 MSEK prior year).

• Net loss after tax for 2024 was -47.8 MSEK, compared to -35.8 MSEK in 2023; Q4 net loss was -15.6 MSEK (-9.5 MSEK prior year).

• Cash flow from operations for 2024 was -12.0 MSEK (-9.1 MSEK prior year); cash at year-end was 0.6 MSEK (1.2 MSEK prior year).

• Equity at year-end was 3.3 MSEK (41.1 MSEK prior year); equity per share was 0.02 SEK (0.39 SEK prior year).

Outlook and guidance

• Initial commercial launch of Sumatriptan Alginatfilm in Germany, Spain, and Italy expected in H2 2025, with further European expansion in 2026.

• Targeting at least one additional licensing agreement outside Europe within the next 12 months.

• Updates on three other development projects anticipated in 2025.